Ischemic Optic Neuropathy News and Research

RSS
Ischemic optic neuropathy (ION) is a condition in which there is significant impairment or loss of vision in the middle-aged or elderly population, especially Caucasians, due to ischemia of the optic nerve head. The incidence in the USA is between 2 and 10 per 100 000 with 6000 new cases being diagnosed each year.
New book provides insights into latest treatments for partial blindness

New book provides insights into latest treatments for partial blindness

USPTO grants key patent for Quark Pharmaceuticals' QPI-1007 ocular neuroprotectant

USPTO grants key patent for Quark Pharmaceuticals' QPI-1007 ocular neuroprotectant

Risk of blindness from spinal-fusion surgery has declined, study shows

Risk of blindness from spinal-fusion surgery has declined, study shows

Transorbital ACS can improve vision in patients with glaucoma, optic nerve damage

Transorbital ACS can improve vision in patients with glaucoma, optic nerve damage

Adding corticosteroid fluocortolone with standard therapy improves visual acuity in NAION patients

Adding corticosteroid fluocortolone with standard therapy improves visual acuity in NAION patients

Findings allay prostatectomy eye pressure concerns

Findings allay prostatectomy eye pressure concerns

Study identifies six risk factors associated with blindness after spine surgery

Study identifies six risk factors associated with blindness after spine surgery

Diopsys launches new Vision Testing System to detect optic nerve disease

Diopsys launches new Vision Testing System to detect optic nerve disease

Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection

Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection

Quark reports results from QPI-1007 siRNA drug study in rat ocular hypertension model of glaucoma

Quark reports results from QPI-1007 siRNA drug study in rat ocular hypertension model of glaucoma

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Vision loss after non-ocular surgery is rare but potentially devastating

Vision loss after non-ocular surgery is rare but potentially devastating

Sleep disorders linked to eye disease

Sleep disorders linked to eye disease

Sleep disorder linked to eye disease

Sleep disorder linked to eye disease

Keep taking Viagra, it won't make you blind!

Keep taking Viagra, it won't make you blind!